Skip to main content
Erschienen in: memo - Magazine of European Medical Oncology 3/2013

01.09.2013 | short review

Biosimilars versus generics: scientific basics and clinical implications

verfasst von: Harald H. Sitte, MD, Michael Freissmuth

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 3/2013

Einloggen, um Zugang zu erhalten

Abstract

Generic drugs contain the identical chemical copy of their cognate originator drug’s active ingredient and this can be proven by their physicochemical properties and the structural identity. A more complex situation is given when it comes to biological drugs, where identical copies cannot be produced. Hence, similar to the approval of the originator biological drug, great care must be employed when approving biosimilar protein drugs. Furthermore, this needs to be continued after the entrance of biological/biosmilar drugs into the market: rigorous pharmacovigilance during their application is the key and the close surveillance of their production is mandatory. In this review, we will highlight the differences between generic and biosimilar drugs and point out what healthcare professionals need to know.
Literatur
2.
Zurück zum Zitat Verbeeck RK, Musuamba FT. The revised EMA guideline for the investigation of bioequivalence for immediate release oral formulations with systemic action. J Pharm Pharm Sci. 2012;15:376–88.PubMed Verbeeck RK, Musuamba FT. The revised EMA guideline for the investigation of bioequivalence for immediate release oral formulations with systemic action. J Pharm Pharm Sci. 2012;15:376–88.PubMed
6.
Zurück zum Zitat Nightingale SL, Morrison JC. Generic drugs and the prescribing physician. JAMA. 1987;258(9):1200–4.PubMedCrossRef Nightingale SL, Morrison JC. Generic drugs and the prescribing physician. JAMA. 1987;258(9):1200–4.PubMedCrossRef
8.
Zurück zum Zitat Kesselheim AS, Misono AS, Lee JL, Stedman MR, Brookhart MA, Choudhry NK, Shrank WH. Clinical equivalence of generic and brand-name drugs used in cardiovascular disease: a systematic review and meta-analysis. JAMA. 2008;300:2514–26.PubMedCrossRef Kesselheim AS, Misono AS, Lee JL, Stedman MR, Brookhart MA, Choudhry NK, Shrank WH. Clinical equivalence of generic and brand-name drugs used in cardiovascular disease: a systematic review and meta-analysis. JAMA. 2008;300:2514–26.PubMedCrossRef
9.
Zurück zum Zitat Gagne JJ, Avorn J, Shrank WH, Schneeweiss S. Refilling and switching of antiepileptic drugs and seizure-related events. Clin Pharmacol Ther. 2010;88:347–53.PubMedCrossRef Gagne JJ, Avorn J, Shrank WH, Schneeweiss S. Refilling and switching of antiepileptic drugs and seizure-related events. Clin Pharmacol Ther. 2010;88:347–53.PubMedCrossRef
10.
Zurück zum Zitat Sauerborn M, Brinks V, Jiskoot W, Schellekens H. Immunological mechanism underlying the immune response to recombinant human protein therapeutics. Trends Pharmacol Sci. 2010;31:53–9.PubMedCrossRef Sauerborn M, Brinks V, Jiskoot W, Schellekens H. Immunological mechanism underlying the immune response to recombinant human protein therapeutics. Trends Pharmacol Sci. 2010;31:53–9.PubMedCrossRef
11.
Zurück zum Zitat Suntharalingam G, Perry MR, Ward S, Brett SJ, Castello-Cortes A, Brunner MD, Panoskaltsis N. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med. 2006;355:1018–28.PubMedCrossRef Suntharalingam G, Perry MR, Ward S, Brett SJ, Castello-Cortes A, Brunner MD, Panoskaltsis N. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med. 2006;355:1018–28.PubMedCrossRef
12.
Zurück zum Zitat Gibbs JP. Prediction of exposure-response relationships to support first-in-human study design. AAPS J. 2010;12:750–8.PubMedCrossRef Gibbs JP. Prediction of exposure-response relationships to support first-in-human study design. AAPS J. 2010;12:750–8.PubMedCrossRef
13.
Zurück zum Zitat Brockmayer C, Seidel A. Binocrit: assessment of quality, safety and efficacy of biopharmaceuticals EJHP Practice. 2009;15(2):34–40. Brockmayer C, Seidel A. Binocrit: assessment of quality, safety and efficacy of biopharmaceuticals EJHP Practice. 2009;15(2):34–40.
14.
Zurück zum Zitat Schiestl M, Stangler T, Torella C, Cepeljnik T, Toll H, Grau R.Acceptable changes in quality attributes of glycosylated biopharmaceuticals. Nat Biotechnol. 2011;29:310–2.PubMedCrossRef Schiestl M, Stangler T, Torella C, Cepeljnik T, Toll H, Grau R.Acceptable changes in quality attributes of glycosylated biopharmaceuticals. Nat Biotechnol. 2011;29:310–2.PubMedCrossRef
15.
Zurück zum Zitat Espinosa-de la Garza CE, Perdomo-Abúndez FC, Padilla-Calderón J, Uribe-Wiechers JM, Pérez NO, Flores-Ortiz LF, Medina-Rivero E. Analysis of recombinant monoclonal antibodies by capillary zone electrophoresis. Electrophoresis. 2013;34:1133–40.PubMedCrossRef Espinosa-de la Garza CE, Perdomo-Abúndez FC, Padilla-Calderón J, Uribe-Wiechers JM, Pérez NO, Flores-Ortiz LF, Medina-Rivero E. Analysis of recombinant monoclonal antibodies by capillary zone electrophoresis. Electrophoresis. 2013;34:1133–40.PubMedCrossRef
16.
Zurück zum Zitat Chirino AJ, Mire-Sluis A. Characterizing biological products and assessing comparability following manufacturing changes. Nat Biotechnol. 2004;22:1383–91.PubMedCrossRef Chirino AJ, Mire-Sluis A. Characterizing biological products and assessing comparability following manufacturing changes. Nat Biotechnol. 2004;22:1383–91.PubMedCrossRef
17.
Zurück zum Zitat Schneider CK. Biosimilars in rheumatology: the wind of change. Ann Rheum Dis. 2013;72:315–8.PubMedCrossRef Schneider CK. Biosimilars in rheumatology: the wind of change. Ann Rheum Dis. 2013;72:315–8.PubMedCrossRef
18.
Zurück zum Zitat Schellekens H, Casadevall N. Immunogenicity of recombinant human proteins: causes and consequences. J Neurol. 2004;251(2):II4–9.PubMed Schellekens H, Casadevall N. Immunogenicity of recombinant human proteins: causes and consequences. J Neurol. 2004;251(2):II4–9.PubMed
19.
Zurück zum Zitat Bennett CL, Luminari S, Nissenson AR, Tallman MS, Klinge SA, McWilliams N, McKoy JM, Kim B, Lyons EA, Trifilio SM, Raisch DW, Evens AM, Kuzel TM, Schumock GT, Belknap SM, Locatelli F, Rossert J, Casadevall N. Pure red-cell aplasia and epoetin therapy. N Engl J Med. 2004;30(351):1403–8.CrossRef Bennett CL, Luminari S, Nissenson AR, Tallman MS, Klinge SA, McWilliams N, McKoy JM, Kim B, Lyons EA, Trifilio SM, Raisch DW, Evens AM, Kuzel TM, Schumock GT, Belknap SM, Locatelli F, Rossert J, Casadevall N. Pure red-cell aplasia and epoetin therapy. N Engl J Med. 2004;30(351):1403–8.CrossRef
20.
Zurück zum Zitat Macdougall IC, Roger SD, Francisco A de, Goldsmith DJ, Schellekens H, Ebbers H, Jelkmann W, London G, Casadevall N, Hörl WH, Kemeny DM, Pollock C. Antibody-mediated pure red cell aplasia in chronic kidney disease patients receiving erythropoiesis-stimulating agents: new insights. Kidney Int. 2012;81:727–32.PubMedCrossRef Macdougall IC, Roger SD, Francisco A de, Goldsmith DJ, Schellekens H, Ebbers H, Jelkmann W, London G, Casadevall N, Hörl WH, Kemeny DM, Pollock C. Antibody-mediated pure red cell aplasia in chronic kidney disease patients receiving erythropoiesis-stimulating agents: new insights. Kidney Int. 2012;81:727–32.PubMedCrossRef
21.
Zurück zum Zitat Pollock C, Johnson DW, Hörl WH, Rossert J, Casadevall N, Schellekens H, Delage R, De Francisco A, Macdougall I, Thorpe R, Toffelmire E. Pure red cell aplasia induced by erythropoiesis-stimulating agents. Clin J Am Soc Nephrol. 2008;3:193–9.PubMedCrossRef Pollock C, Johnson DW, Hörl WH, Rossert J, Casadevall N, Schellekens H, Delage R, De Francisco A, Macdougall I, Thorpe R, Toffelmire E. Pure red cell aplasia induced by erythropoiesis-stimulating agents. Clin J Am Soc Nephrol. 2008;3:193–9.PubMedCrossRef
22.
Zurück zum Zitat Macdougall IC, Rossert J, Casadevall N, Stead RB, Duliege AM, Froissart M, Eckardt KU. A peptide-based erythropoietin-receptor agonist for pure red-cell aplasia. N Engl J Med. 2009;361:1848–55.PubMedCrossRef Macdougall IC, Rossert J, Casadevall N, Stead RB, Duliege AM, Froissart M, Eckardt KU. A peptide-based erythropoietin-receptor agonist for pure red-cell aplasia. N Engl J Med. 2009;361:1848–55.PubMedCrossRef
23.
Zurück zum Zitat Shimizu H, Saitoh T, Ota F, Jimbo T, Tsukada Y, Murakami H, Nojima Y. Pure red cell aplasia induced only by intravenous administration of recombinant human erythropoietin. Acta Haematol. 2011;126:114–8.PubMedCrossRef Shimizu H, Saitoh T, Ota F, Jimbo T, Tsukada Y, Murakami H, Nojima Y. Pure red cell aplasia induced only by intravenous administration of recombinant human erythropoietin. Acta Haematol. 2011;126:114–8.PubMedCrossRef
24.
Zurück zum Zitat Schellekens H, Jiskoot W. Eprex-associated pure red cell aplasia and leachates. Nat Biotechnol. 2006;24:613–4.PubMedCrossRef Schellekens H, Jiskoot W. Eprex-associated pure red cell aplasia and leachates. Nat Biotechnol. 2006;24:613–4.PubMedCrossRef
25.
Zurück zum Zitat Seidl A, Hainzl O, Richter M, Fischer R, Böhm S, Deutel B, Hartinger M, Windisch J, Casadevall N, London GM, Macdougall I. Tungsten-induced denaturation and aggregation of epoetin alfa during primary packaging as a cause of immunogenicity. Pharm Res. 2012;29:1454–67.PubMedCrossRef Seidl A, Hainzl O, Richter M, Fischer R, Böhm S, Deutel B, Hartinger M, Windisch J, Casadevall N, London GM, Macdougall I. Tungsten-induced denaturation and aggregation of epoetin alfa during primary packaging as a cause of immunogenicity. Pharm Res. 2012;29:1454–67.PubMedCrossRef
26.
Zurück zum Zitat Weise M, Bielsky MC, De Smet K, Ehmann F, Ekman N, Giezen TJ, Gravanis I, Heim HK, Heinonen E, Ho K, Moreau A, Narayanan G, Kruse NA, Reichmann G, Thorpe R, Aerts L van, Vleminckx C, Wadhwa M, Schneider CK. Biosimilars: what clinicians should know. Blood. 2012;120:5111–7.PubMedCrossRef Weise M, Bielsky MC, De Smet K, Ehmann F, Ekman N, Giezen TJ, Gravanis I, Heim HK, Heinonen E, Ho K, Moreau A, Narayanan G, Kruse NA, Reichmann G, Thorpe R, Aerts L van, Vleminckx C, Wadhwa M, Schneider CK. Biosimilars: what clinicians should know. Blood. 2012;120:5111–7.PubMedCrossRef
28.
Zurück zum Zitat Schneider CK, Kalinke U. Toward biosimilar monoclonal antibodies. Nat Biotechnol. 2008;26:985–90.PubMedCrossRef Schneider CK, Kalinke U. Toward biosimilar monoclonal antibodies. Nat Biotechnol. 2008;26:985–90.PubMedCrossRef
29.
Zurück zum Zitat Brinks V, Jiskoot W, Schellekens H. Immunogenicity of therapeutic proteins: the use of animal models. Pharm Res. 2011;28:2379–85.PubMedCrossRef Brinks V, Jiskoot W, Schellekens H. Immunogenicity of therapeutic proteins: the use of animal models. Pharm Res. 2011;28:2379–85.PubMedCrossRef
31.
Zurück zum Zitat Declerck PJ. Biosimilar monoclonal antibodies: a science-based regulatory challenge. Expert Opin Biol Ther. 2013;13:153–6.PubMedCrossRef Declerck PJ. Biosimilar monoclonal antibodies: a science-based regulatory challenge. Expert Opin Biol Ther. 2013;13:153–6.PubMedCrossRef
Metadaten
Titel
Biosimilars versus generics: scientific basics and clinical implications
verfasst von
Harald H. Sitte, MD
Michael Freissmuth
Publikationsdatum
01.09.2013
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 3/2013
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-013-0094-8

Weitere Artikel der Ausgabe 3/2013

memo - Magazine of European Medical Oncology 3/2013 Zur Ausgabe